Dara L. Aisner

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline

  JCO Oncology Practice · 2026-06-18

• High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase Inhibitors

  Clinical Lung Cancer · 2026-04-30

• Recommended Terms and Definitions From the 2025 NCCN Biomarkers Resource Committee

  Journal of the National Comprehensive Cancer Network · 2026-04-27

• Copy Number-low/TP53-mutated Endometrial Cancer With Wild-type p53 Immunoexpression: Implications for Risk Stratification and Management When Using Next-generation Sequencing for Molecular Classification

  Modern Pathology · 2026-04-21

• Non–Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology

  Journal of the National Comprehensive Cancer Network · 2026-04-01 · 5 citations

• Longitudinal, Retrospective Use of a Circulating Tumor DNA Methylation Signature Successfully Captures Small Cell Evolution in a Patient With Metastatic EGFR-Mutant Non–Small Cell Lung Cancer

  JCO Precision Oncology · 2026-04-01

• 970 Endometrial Carcinomas Are Enriched for Acetylsalicylic Acid (ASA)-Associated PI3K Pathway Mutations

  Laboratory Investigation · 2026-03-01

• Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy

  Haematologica · 2026-02-26

• All for One and One for All? The Role of RNA-Based Next-Generation Sequencing in the Molecular Profiling of Tumors

  Clinical Chemistry · 2026-01-21

• High programmed death-ligand 1 expression is associated with a shorter progression free survival in ALK-rearranged lung cancer patients treated with first line tyrosine kinase inhibitorsPreprint

  SSRN Electronic Journal · 2026-01-01

• NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 7.2025

  Journal of the National Comprehensive Cancer Network · 2025-09-01 · 47 citations

• Characteristics of Short-Term Survivors With ALK or ROS1-Altered Metastatic NSCLC

  JTO Clinical and Research Reports · 2025-07-03

• A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial

  Clinical Cancer Research · 2025-06-04 · 1 citations

• Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology

  Journal of the National Comprehensive Cancer Network · 2025-06-01 · 23 citations

• Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis

  Lung Cancer · 2025-04-19 · 5 citations

• 983 ARID1A Immunohistochemistry (IHC) Shows Low Sensitivity for ARID1A Mutation by Next Generation Sequencing (NGS) in Endometrial Carcinomas

  Laboratory Investigation · 2025-03-01

• Novel PLEC-EML4-ALK Double Fusion Underlying Crizotinib Resistance in a Metastatic Inflammatory Myofibroblastic Tumor: A Case Report

  JTO Clinical and Research Reports · 2025-01-07

• 40: Mixing ploidies and assays: A case report of perinatal diagnosis and outcome for diploid/triploid mixoploidy

  Genetics in Medicine Open · 2025-01-01

• Clinical and Radiographic Benefit of a Patient With Metastatic Non-Small Cell Lung Cancer Harboring an <i>EGFR::ERBB4</i> Fusion Through Use of EGFR Tyrosine Kinase Inhibitors

  JCO Precision Oncology · 2024-12-01 · 2 citations

• The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations

  Lung Cancer · 2024-11-25 · 10 citations